Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus

Figure 1 Flow diagram of hepatocellular carcinoma with portal vein tumor thrombus patients treated with transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors or transarterial arterial chemoembolization combined with lenvatinib therapy. ECOG: Eastern Cooperative Oncology Group; HCC-PVTT: Hepatocellular carcinoma with portal vein tumor thrombus; PSM: Propensity score matching; TACE: Transarterial arterial chemoembolization; TACE-L-P: Transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors; TACE-L: Transarterial arterial chemoembolization combined with lenvatinib.